Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: Effects of α1-acid glycoprotein

Journal of Clinical Pharmacology

Volumn 36, Issue 11, 1996, Pages 1029-1038

  Koiso, Kenkichi ^a   Akaza, Hideyuki ^a   Kikuchi, Koji ^a   Aoyagi, Kazumasa ^a   Ohba, Shoji ^b   Miyazaki, Mitsuhiro ^c   Ito, Mitsue ^d   Sueyoshi, Toshiyuki ^e   Matsushima, Hiroshi ^e   Kamimura, Hidetaka ^e   Watanabe, Takashi ^e   Higuchi, Saburo ^e  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Mito Central Hospital   (Japan)

^c HITACHI LTD   (Japan)

^d Kan nondai Clinic   (Japan)

^e ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; OROSOMUCOID; TAMSULOSIN;

ADULT; AGED; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG PROTEIN BINDING; DRUG URINE LEVEL; DYSURIA; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MALE; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY;

EID: 8044231317     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127009603601107     Document Type: Article

References (31)

1. Honda K, Nakagawa C: Alpha-1 adrenoceptor antagonistic effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 1986;239:512-516.
2. 1-adrenoceptor anatgonist and its individual optical enantiomers. Naunyn Schmiedebergs Arch Pharmacol 1987;336:295-302.
3. Paxton JW, Briant RH: Alpha-1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. Br J Clin Pharmacol 1984;18:806-810.
4. Lipton A, Harvey HA, Delong S, Allegra J, White D, Allegra M Davidson EA: Glycoproteins and human cancer. I. Circulating levels in cancer serum. Cancer 1979;43:1766-1771.
5. Jackson PR, Tucker GT, Woods HF: Altered plasma drug binding in cancer: role of alpha-1-acid glycoprotein and albumin. Clin Pharmacol Ther 1982;32:295-302.
6. Agostoni A, Vergani C, Stabilini R, Marasini B, Arcidiacono R, Sbaffi A, Binagi PC: Immochemical quantitation of acute phase reactive proteins in myocardial infarction. Am Heart J 1970;80:313-318.
7. Barchowsky A, Shand DG, Stargle WW, Wagner GS, Routledge PA: On the role of alpha-1-acid glycoprotein in lignocaine accumulation following myocardial infarction, Br J Clin Pharmacol 1982;13:411-415.
8. David BM, Ilett KF, Witford EG, Stenhouse NS: Prolonged vari4 ability in plasma binding of disopyramide after acute myocardial infarction. Br J Clin Pharmacol 1983;15:435-441.
9. Edward DJ, Lalka D, Cerra F, Slaughter RL: Alpha-1-acid glycoprotein concentrations and protein binding in trauma. Clin Pharmacol Ther 1982;31:62-67.
10. Edward DJ, Axelson JE, Slaughter RL, Elvin AT, Lalka D: Factors affecting quinidine protein binding in humans. J Pharm Sci 1984;73:1264-1269.
11. Piafsky KM, Borgå O, Odar-Cederlöf I, Johansson C, Sjöqvist F: Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha-1-acid glycoprotein. N Engl J Med 1978;299:1435-1439.
12. Grossman SH, Davis D, Kitchell BB, Shand DG, Routledge PA: Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Ther 1982;31:350-357.
13. Terao N, Shen DD: Alterations in serum protein binding and pharmacokinetics of 1-propranolol in the rat elicited by the presence of an indwelling venous catheter. J Pharmacol Exp Ther 1983;227:369-375.
14. Yasuhara M, Fujiwara J, Kitade S, Katayama H, Okumura K, Hori R: Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. J Pharmacol Exp Ther 1985;235:513-520.
15. Kwong TC: Free drug measurements: methodology and clinical significance. Clin Chim Acta 1985;151:193-216.
16. Barre J, Didey F, Delion F, Tillement JP: Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988;10:133-143.
17. Matsushima H, Takanuki K, Kamimura H, Watanabe T, Higuchi S: Highly sensitive method for the determination of tamsulosin hydrochloride in plasma dialysate, plasma and urine by high performance liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr, submitted.
18. Soeishi Y, Kobori M, Kobayashi S, Higuchi S: Sensitive method for the determination of amsulosin in human plasma using high-performance liquid chromatography with fluorescence detection. J Chromatogr 1990;533:291-296.
19. 1-adrenoceptor antagonist, in man, and interspecies scaling versus preclinical data. Presented at the Fourth International ISSX Meeting. Seattle. WA, August 27-31, 1995.
20. Sjöholm I, Kober A, Odar-Cerderlöf I, Borgå O: Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 1976;25:1205-1213.
21. McNamara PJ, Lalka D, Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 1981;98:730-740.
22. Levi G, Lai CM, Yacobi A: Comparative pharmacokinetics of coumarin anticoagulants. XXXII. Interindividual differences in binding of warfarin and dicumarol in rat liver and implications for physiological pharmacokinetic modeling. J Pharm Sci 1978;67:229-231.
23. Evans GH, Nies AS, Shand DG: The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther 1973;186:114-122.
24. Huang JD, Øie S: Effect of altered disopyramide binding on its pharmacologic response in rabbits. J Pharmacol Exp Ther 1982;223:469-471.
25. McDevitt DG, Frisk-Holmber M, Hollifield JW, Shand DG: Plasma binding and affinity of propranolol for a beta receptor in man. Clin Pharmacol Ther 1976;20:152-157.
26. Braun J, Sörgel F, Gluth WP, Øie S: Does alpha-1-acid glycoprotein reduce unbound metabolic clearance of disopyramide in patients with renal impairment? Eur J Clin Pharmacol 1988;35:313-317.
27. 1-acid glycoprotein in the rat in vivo. J Pharmacol Exp Ther 1987;241:934-938.
28. Øie S, Fiori F: Effects of albumin and alpha-1-acid glycoprotein on elimination of prazosin and antipyrine in the isolated perfused rat liver. J Pharmacol Exp Ther 1985;234:636-640.
29. 1-acid glycoprotein on quinine and quinidine disposition in the rat isolated perfused liver preparation. J Pharm Pharmacol 1990;43:650-654.
30. Qin M, Nilsson M, Øie S: Decrease elimination of drug in the presence of alpha-1-acid glycoprotein is related to a reduced hepatocyte uptake. J Pharmacol Exp Ther 1994;269:1176-1181.
31. Lowenthal DT, Hobbs D, Affrime MB, Twomey TM, Martinez EW, Onesti G: Prazosin kinetics and effectiveness in renal failure. Clin Pharmacol Ther 1980;27:779-783.